Table 3.
Key checkpoint inhibitor trials (ClinicalTrials.gov identifiers) in urothelial carcinoma.
| Setting | Drug | Phase |
|---|---|---|
| Metastatic | ||
| NCT02335424 | Pembrolizumab in cisplatin ineligible | II |
| NCT02256436 | Pembrolizumab (versus paclitaxel, docetaxel, or vinflunine) | III |
| NCT02108652 | Atezolizumab | II |
| NCT02302807 | Atezolizumab versus chemotherapy | III |
| NCT01848834 | Pembrolizumab | Ib |
| NCT02387996 | Nivolumab post cisplatin | II |
| NCT01524991 | Ipilimumab (plus gemcitabine and cisplatin) | II |
| Neoadjuvant | ||
| NCT02365766 | Pembrolizumab | Ib/II |
| Adjuvant | ||
| NCT02450331 | Atezolizumab versus observation | III |